Disc Medicine (IRON) Total Debt (2020 - 2026)
Disc Medicine (IRON) posted quarterly Total Debt of $59.3 million for Q2 2026, up 106.49% year-over-year from $28.7 million in Q2 2025, and up 102.08% quarter-over-quarter from $29.4 million in Q1 2026.
Analysis
Disc Medicine (IRON) Total Debt (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Total Debt for 6 consecutive years, with $59.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Debt rose 106.49% year-over-year to $59.3 million; the TTM figure through Jun 2026 stood at $59.3 million (up 106.49% YoY), while the FY2025 annual figure was $29.2 million, up 2.96% from the prior year.
- Total Debt grew to $59.3 million in Q2 2026 per IRON's latest filing, from $29.4 million in the prior quarter.
- Across five years, Total Debt topped out at $59.3 million in Q2 2026 and bottomed at $2.9 million in Q2 2022.
- Historically, Total Debt has averaged $26.6 million across 4 years, with a median of $28.7 million in 2025.
- Annual changes were most pronounced in 2022 — Total Debt sank 63.08% — and 2026, when it surged 106.49%.
- Disc Medicine's Total Debt stood at $2.9 million in 2022, then surged by 872.26% to $28.3 million in 2024, then rose by 2.96% to $29.2 million in 2025, then soared by 103.5% to $59.3 million in 2026.
- Business Quant data shows IRON's Total Debt at $59.3 million in Q2 2026, $29.4 million in Q1 2026, and $29.2 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 591.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.07 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.34 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | 59.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.34 Mn |
| Mar 31, 2026 | 29.37 Mn |
| Dec 31, 2025 | 29.16 Mn |
| Sep 30, 2025 | 28.95 Mn |
| Jun 30, 2025 | 28.74 Mn |
| Mar 31, 2025 | 28.53 Mn |
| Dec 31, 2024 | 28.32 Mn |
| Jun 30, 2022 | 2.91 Mn |
| Mar 31, 2022 | 4.16 Mn |
| Dec 31, 2021 | 11.85 Mn |
| Sep 30, 2021 | 6.65 Mn |
| Jun 30, 2021 | 7.89 Mn |
| Mar 31, 2021 | 9.13 Mn |
| Dec 31, 2020 | 21.64 Mn |